The U.S. Judicial Panel on Multidistrict Litigation (JPML) has accepted a motion filed by a group of plaintiffs to centralize all Bard IVC filter lawsuits as part of one coordinated litigation process. The federal multidistrict litigation formed by the panel (MDL No. 2641, In Re:... Read More

Thirteen plaintiffs have filed a joint Xarelto internal bleeding lawsuit over injuries allegedly sustained in connection to the popular new blood thinner. Injuries include severe gastrointestinal bleeding and brain hemorrhage, and ultimately resulted in the death of three plaintiffs (represented by their next of kin).... Read More

On the heals of Takeda Pharmaceuticals reaching a multi-billion dollar settlement agreement with thousands of Actos bladder cancer plaintiffs, a new study raises concerns about additional side effects of the drug, including increased risk of pancreatic and prostate cancers. The study, published in The Journal... Read More

A medical research bill with a device safety provision inspired by the controversy over power morcellator side effects passed the House of Representatives on July 10. While the bill as a whole includes several provisions encouraging federal funding for medical research and further regulations regarding... Read More

GlaxoSmithKline (GSK), the manufacturer of an anti-nausea drug at the center of controversy over the harm it allegedly causes developing fetuses, has filed a motion to centralize all Zofran lawsuits alleging birth defects before one judge. The manufacturer has petitioned for the establishment of a federal... Read More

A NaturaLyte lawsuit alleging heart injury was filed on July 1 of this year on behalf of a decedent who experienced a “severe adverse cardiovascular event” while receiving dialysis treatment at a Fresenius clinic. According to the complaint, Marshall Russell Phillips was stricken on July... Read More

Lawyers for plaintiffs who have filed power morcellator lawsuits alleging the devices spread cancer have submitted a motion to centralize the complaints before one judge as part of a single litigation process. Currently, at least 22 such cases have been filed concerning women who have diagnosed... Read More

Health Canada has announced that it will begin a safety review of (canagliflozin) Invokana and (dapagliflozin) Forxiga, medications which are part of a new class of drugs known as SGLT2 inhibitors that are approved to treat type 2 diabetes. The review will investigate possible Invokana... Read More